RAS inhibitors in hematologic cancers: biologic considerations and clinical applications.
As the molecular mechanisms responsible for the development and propagation of cancer are becoming elucidated, the nascent field of gene-directed therapy is emerging. Recently, several investigators have described inhibitors of the Ras protein. This molecule has been targeted because RAS is one of the most commonly mutated oncogenes in human neoplasia. In this review, we will discuss the role of Ras in the pathogenesis of hematologic neoplasms, and the biology behind the development of novel compounds which specifically suppress Ras function.
Beaupre
D M
DM
Department of Internal Medicine, The University of Miami Jackson Memorial Hospital and the VA Medical Center, Florida, USA.
Kurzrock
R
R
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D018631:ras Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology*
D018631:ras Proteins